CRDF News and Press, Cardiff Oncology Inc. From 09/14/20

SAN DIEGO , Sept. 14, 2020 /PRNewswire/ --  Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-res...

Cardiff Oncology (NASDAQ: CRDF ) : Q2 GAAP EPS of -$0.51 misses by $0.27 . More news on: Cardiff Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO , Aug. 11, 2020 /PRNewswire/ --  Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castrate-resistant p...

SAN DIEGO , Aug. 4, 2020 /PRNewswire/ --  Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resis...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...